CDXS Codexis

Codexis to Participate in Upcoming Healthcare Conferences

Codexis to Participate in Upcoming Healthcare Conferences

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in four upcoming investor conferences.

The Jefferies London Healthcare Conference (London, UK)  

  • Tuesday, November 14, 2023, at 1:00 pm GMT, management will participate in a fireside chat

The Stifel 2023 Healthcare Conference (New York, NY)

  • Tuesday, November 14, 2023, at 9:10 am ET, management will participate in a fireside chat

The Stephens Annual Investment Conference (Nashville, TN)

  • Wednesday, November 15, 2023, at 9:00 am CT, management will participate in a fireside chat

The 14th Annual Craig-Hallum Alpha Select Conference (New York, NY)

  • Thursday, November 16, 2023, management will host 1x1 investor meetings

Live webcasts of each fireside chat will be available on the Investor Relations section of the Company’s website, . A replay of each fireside chat will be archived for 90 days following the presentation date.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit .

For More Information

Investor Contact

Carrie McKim

(336) 608-9706

Media Contact

Lauren Musto

(781) 572-1147



EN
31/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

 PRESS RELEASE

Codexis Reports Second Quarter 2025 Financial Results

Codexis Reports Second Quarter 2025 Financial Results Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quart...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch